Establishment Labs Receives U.S. FDA Approval for Motiva Implants
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
BTIG Reiterates Buy Rating on Establishment Labs Inc. (ESTA)
September 27, 2024 6:12 AM EDTBTIG analyst Marie Thibault reiterated a Buy rating and $62.00 price target on Establishment Labs Inc. (NASDAQ: ESTA).
The analyst comments "Today after the close, Establishment Labs announced that the FDA approved the Motiva Ergonomix and Round breast implants for primary and revision breast augmentation. This marks the first new breast implant PMA approval since 2013.... More
